<DOC>
	<DOCNO>NCT02316912</DOCNO>
	<brief_summary>First man evaluation single multiple dos compound ATX2417 healthy male volunteer . A double blind placebo control parallel group ascend dose design ; five dose level single dose two dose level multiple dose ( 8 day dose ) . Subjects screen assure normal health prior inclusion trial monitor safety ( adverse event , vital sign , ECGs , safety lab ) pharmacokinetic profile . A fasted/fed comparison also include single ascend dose part trial .</brief_summary>
	<brief_title>First Man Evaluation Single Multiple Doses Oral ATX2417</brief_title>
	<detailed_description>The study consist two part , A ( single ascend dose include fasted/fed comparison ) B ( multiple ascend dose ) . Part B conduct thorough review Sponsor Principal Investigator data arise part A . Part A This randomise , double blind , placebo control , parallel group titration seven single dose level ATX2417 . In cohort , six subject receive active compound two receive placebo randomise fashion . At dose level , 2 subject ( 1 subject receive ATX2417 1 subject receive placebo ) dose Day 1 remain 6 subject dose least 24 hour later . Safety pharmacokinetic observation make . There minimum two week first dose day dose level . Safety ATX2417 pharmacokinetic data review prior dose escalation , base pharmacokinetic data , also possible decrease dose pharmacokinetic profile indicate . This part also include assessment effect high fat breakfast absorption pharmacokinetic profile ATX 2417 , perform dose predict associate therapeutic plasma concentration . Part B Following completion Part A , selection appropriate dose level , Part B perform . This randomise , double blind , placebo control , parallel group study two dose level ATX2417 give daily eight day . In cohort , six subject receive active compound two receive placebo randomise fashion . Safety pharmacokinetic observation make .</detailed_description>
	<criteria>1 . Healthy male subject , racial group 2 . Able comply protocol 3 . Subjects Body Mass Index ( BMI ) 2128 ( BMI = Body weight ( kg ) / ( Height ( ) 2 ) 1 . A history gastrointestinal disorder likely influence drug absorption 2 . Receipt medication include counter preparation vitamin within 14 day first dose study drug exception paracetamol maximum 2 g daily 3 . Evidence clinically significant renal , hepatic , cardiovascular metabolic dysfunction 4 . A history drug alcohol abuse 5 . Inability communicate well investigator ( i.e. , language problem , poor mental development impair cerebral function )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>allergy</keyword>
</DOC>